A 14-year study of serum glial fibrillary acidic protein and total tau in premanifest Huntington's

Natalia E. Owen; Zanna J. Voysey; Jonathan A. Holbrook; Maura Malpetti; Clara Le Draoulec; Lennart R. B. Spindler; Anna O. G. Goodman; Alpar S. Lazar; Roger A. Barker

doi:10.1002/acn3.70057

A 14-year study of serum glial fibrillary acidic protein and total tau in premanifest Huntington's

Natalia E. Owen, Zanna J. Voysey, Jonathan A. Holbrook, Maura Malpetti, Clara Le Draoulec, Lennart R. B. Spindler, Anna O. G. Goodman, Alpar S. Lazar, Roger A. Barker

Research output: Contribution to journal › Article › peer-review

Abstract

There is a pressing need for blood biomarkers that can identify Huntington's disease (HD) gene carriers' proximity to manifest disease. We previously examined serial serum neurofilament light (NfL) concentrations in 21 premanifest HD gene carriers and 14 controls over 14 years, finding that NfL demonstrates high prognostic value and distinct longitudinal dynamics in premanifest/transitional HD. Here, we report the corresponding results for serum glial fibrillary acidic protein and total tau, providing the first longitudinal and head-to-head study of these biomarkers in HD. Our findings do not support the utility of these analytes as prognostic biomarkers in premanifest and transitional HD.

Original language	English
Pages (from-to)	1296-1301
Number of pages	6
Journal	Annals of Clinical and Translational Neurology
Volume	12
Issue number	6
Early online date	21 Apr 2025
DOIs	https://doi.org/10.1002/acn3.70057
Publication status	Published - Jun 2025

Keywords

Huntington's disease
blood-based biomarkers
glial fibrillary acidic protein
prognostic biomarkers
tau

Access to Document

10.1002/acn3.70057Licence: CC BY

Owen-etal-2025-AnnClinTranslNeurolFinal published version, 1.17 MBLicence: CC BY

https://onlinelibrary.wiley.com/doi/10.1002/acn3.70057Licence: CC BY

Cite this

@article{9ff168af5ce54838abb3846786c876f1,

title = "A 14-year study of serum glial fibrillary acidic protein and total tau in premanifest Huntington's",

abstract = "There is a pressing need for blood biomarkers that can identify Huntington's disease (HD) gene carriers' proximity to manifest disease. We previously examined serial serum neurofilament light (NfL) concentrations in 21 premanifest HD gene carriers and 14 controls over 14 years, finding that NfL demonstrates high prognostic value and distinct longitudinal dynamics in premanifest/transitional HD. Here, we report the corresponding results for serum glial fibrillary acidic protein and total tau, providing the first longitudinal and head-to-head study of these biomarkers in HD. Our findings do not support the utility of these analytes as prognostic biomarkers in premanifest and transitional HD.",

keywords = "Huntington's disease, blood-based biomarkers, glial fibrillary acidic protein, prognostic biomarkers, tau",

author = "Owen, {Natalia E.} and Voysey, {Zanna J.} and Holbrook, {Jonathan A.} and Maura Malpetti and {Le Draoulec}, Clara and Spindler, {Lennart R. B.} and Goodman, {Anna O. G.} and Lazar, {Alpar S.} and Barker, {Roger A.}",

note = "Data Availability Statement: The data that support the findings of this study are available upon request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Funding: This work was supported by Centre Parkinson Plus Grant and Cure Parkinson's Trust; Association of British Neurologists/Guarantors of Brain, Clinical Research Fellowship; Wellcome Trust (203151/A/16/Z, 203151/Z/16/Z); NIHR Cambridge Biomedical Research Centre (BRC-1215-20014); UKRI Medical Research Council (MC_PC_17230); Alzheimer's Research UK (ARUK-RADF2021A-010); UK Medical Research Council.",

year = "2025",

month = jun,

doi = "10.1002/acn3.70057",

language = "English",

volume = "12",

pages = "1296--1301",

journal = "Annals of Clinical and Translational Neurology",

issn = "2328-9503",

publisher = "Wiley",

number = "6",

}

TY - JOUR

T1 - A 14-year study of serum glial fibrillary acidic protein and total tau in premanifest Huntington's

AU - Owen, Natalia E.

AU - Voysey, Zanna J.

AU - Holbrook, Jonathan A.

AU - Malpetti, Maura

AU - Le Draoulec, Clara

AU - Spindler, Lennart R. B.

AU - Goodman, Anna O. G.

AU - Lazar, Alpar S.

AU - Barker, Roger A.

N1 - Data Availability Statement: The data that support the findings of this study are available upon request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Funding: This work was supported by Centre Parkinson Plus Grant and Cure Parkinson's Trust; Association of British Neurologists/Guarantors of Brain, Clinical Research Fellowship; Wellcome Trust (203151/A/16/Z, 203151/Z/16/Z); NIHR Cambridge Biomedical Research Centre (BRC-1215-20014); UKRI Medical Research Council (MC_PC_17230); Alzheimer's Research UK (ARUK-RADF2021A-010); UK Medical Research Council.

PY - 2025/6

Y1 - 2025/6

N2 - There is a pressing need for blood biomarkers that can identify Huntington's disease (HD) gene carriers' proximity to manifest disease. We previously examined serial serum neurofilament light (NfL) concentrations in 21 premanifest HD gene carriers and 14 controls over 14 years, finding that NfL demonstrates high prognostic value and distinct longitudinal dynamics in premanifest/transitional HD. Here, we report the corresponding results for serum glial fibrillary acidic protein and total tau, providing the first longitudinal and head-to-head study of these biomarkers in HD. Our findings do not support the utility of these analytes as prognostic biomarkers in premanifest and transitional HD.

AB - There is a pressing need for blood biomarkers that can identify Huntington's disease (HD) gene carriers' proximity to manifest disease. We previously examined serial serum neurofilament light (NfL) concentrations in 21 premanifest HD gene carriers and 14 controls over 14 years, finding that NfL demonstrates high prognostic value and distinct longitudinal dynamics in premanifest/transitional HD. Here, we report the corresponding results for serum glial fibrillary acidic protein and total tau, providing the first longitudinal and head-to-head study of these biomarkers in HD. Our findings do not support the utility of these analytes as prognostic biomarkers in premanifest and transitional HD.

KW - Huntington's disease

KW - blood-based biomarkers

KW - glial fibrillary acidic protein

KW - prognostic biomarkers

KW - tau

UR - http://www.scopus.com/inward/record.url?scp=105003298200&partnerID=8YFLogxK

U2 - 10.1002/acn3.70057

DO - 10.1002/acn3.70057

M3 - Article

SN - 2328-9503

VL - 12

SP - 1296

EP - 1301

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

IS - 6

ER -

A 14-year study of serum glial fibrillary acidic protein and total tau in premanifest Huntington's

Abstract

Keywords

Access to Document

Other files and links

Cite this